BTIG analyst Robert Hazlett names Axsome Therapeutics (AXSM) as his BTIG Top Pick for first half of 2023, replacing Eiger BioPharmaceuticals (EIGR) on that list. The company finally received FDA approval of Auvelity – its novel dextromethorphan / bupropion combination for the treatment of major depressive disorder – and the labeling of the molecule in MDD is viewed as "solid and differentiating", the analyst tells investors in a research note. Hazlett has a Buy rating and a $98 price target on the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics price target raised to $98 from $62 at BTIG
- AXSOME call volume above normal and directionally bullish
- Axsome Therapeutics presents data on EVOLVE open-label trial of AUVELITY
- Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
- Biotech Alert: Searches spiking for these stocks today